Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Hold rating on Fate Therapeutics (FATE – Research Report). The ...

Fate Therapeutics Inc (FATE) stock saw a decline, ending the day at $1.83 which represents a decrease of $-0.09 or -4.69% from the prior close of $1.92. The stock opened at $1.97 and touched a low of ...

Fate Therapeutics has announced encouraging initial data from the FT819 phase 1 autoimmunity study for people with ...

In a report released today, Peter Lawson from Barclays assigned a Buy rating to Fate Therapeutics (FATE – Research Report), with a price target ...

On Monday, Fate Therapeutics Inc (FATE) stock saw a modest uptick, ending the day at $2.72 which represents a slight increase of $0.07 or 2.64% from the prior close of $2.65. The stock opened at $ and ...

About Fate Therapeutics’ iPSC Product Platform Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Fate Therapeutics' iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications. About Fate Therapeutics, Inc. Fate ...